Kathryn Romano - May 19, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Kathryn Romano
Stock symbol
KRYS
Transactions as of
May 19, 2023
Transactions value $
-$2,673,990
Form type
4
Date filed
5/23/2023, 04:23 PM
Previous filing
Feb 28, 2023
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $653K +12.5K +78.2% $52.26 28.5K May 19, 2023 Direct F1
transaction KRYS Common Stock Sale -$1.19M -12.5K -43.88% $95.05 16K May 19, 2023 Direct F1, F2
transaction KRYS Common Stock Options Exercise $653K +12.5K +78.2% $52.26 28.5K May 19, 2023 Direct F1
transaction KRYS Common Stock Sale -$1.19M -12.5K -43.88% $95.04 16K May 19, 2023 Direct F1, F2
transaction KRYS Common Stock Sale -$326K -3.43K -21.45% $95.08 12.6K May 19, 2023 Direct F2, F3
transaction KRYS Common Stock Options Exercise $132K +2.52K +20.08% $52.26 15.1K May 22, 2023 Direct F4
transaction KRYS Common Stock Sale -$267K -2.52K -16.72% $105.80 12.6K May 22, 2023 Direct F4, F5
transaction KRYS Common Stock Options Exercise $134K +2.57K +20.47% $52.26 15.1K May 22, 2023 Direct F4
transaction KRYS Common Stock Sale -$274K -2.57K -16.99% $106.81 12.6K May 22, 2023 Direct F4, F6
transaction KRYS Common Stock Options Exercise $67.9K +1.3K +10.35% $52.26 13.9K May 22, 2023 Direct F4
transaction KRYS Common Stock Sale -$140K -1.3K -9.38% $107.88 12.6K May 22, 2023 Direct F4, F7
transaction KRYS Common Stock Options Exercise $154K +2.96K +23.53% $52.26 15.5K May 22, 2023 Direct F4
transaction KRYS Common Stock Sale -$323K -2.96K -19.05% $109.17 12.6K May 22, 2023 Direct F4, F8
transaction KRYS Common Stock Options Exercise $165K +3.15K +25.12% $52.26 15.7K May 22, 2023 Direct F4
transaction KRYS Common Stock Sale -$347K -3.15K -20.08% $109.99 12.6K May 22, 2023 Direct F4, F9
transaction KRYS Common Stock Options Exercise $794K +12.5K +99.55% $63.55 25.1K May 22, 2023 Direct F10
transaction KRYS Common Stock Sale -$1.38M -12.5K -49.89% $110.00 12.6K May 22, 2023 Direct F10, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -12.5K -25% $0.00 37.5K May 19, 2023 Common Stock 12.5K $52.26 Direct F1, F12
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -12.5K -33.33% $0.00 25K May 19, 2023 Common Stock 12.5K $52.26 Direct F1, F12
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -12.5K -50% $0.00 12.5K May 22, 2023 Common Stock 12.5K $52.26 Direct F4, F12
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -12.5K -25% $0.00 37.5K May 22, 2023 Common Stock 12.5K $63.55 Direct F10, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share.
F2 The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates sales of 3,428 shares with a limit price of $95.00 per share.
F4 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.
F5 The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8 The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 The transaction was executed in multiple trades ranging from $109.9700 to $110.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.
F11 The transaction was executed in a single trade.
F12 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021.
F13 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.